Oregon Public Employees Retirement Fund Has $796,000 Stake in Haemonetics Co. (NYSE:HAE)

Oregon Public Employees Retirement Fund decreased its holdings in shares of Haemonetics Co. (NYSE:HAE) by 1.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,192 shares of the medical instruments supplier’s stock after selling 200 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Haemonetics were worth $796,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in HAE. Skylands Capital LLC raised its position in Haemonetics by 16.6% during the fourth quarter. Skylands Capital LLC now owns 27,175 shares of the medical instruments supplier’s stock worth $2,122,000 after acquiring an additional 3,875 shares in the last quarter. Keene & Associates Inc. raised its position in Haemonetics by 7.2% during the fourth quarter. Keene & Associates Inc. now owns 10,904 shares of the medical instruments supplier’s stock worth $851,000 after acquiring an additional 730 shares in the last quarter. Cardinal Capital Management raised its position in Haemonetics by 5.4% during the fourth quarter. Cardinal Capital Management now owns 18,284 shares of the medical instruments supplier’s stock worth $1,428,000 after acquiring an additional 935 shares in the last quarter. Peregrine Capital Management LLC raised its position in Haemonetics by 1.7% during the fourth quarter. Peregrine Capital Management LLC now owns 141,803 shares of the medical instruments supplier’s stock worth $11,072,000 after acquiring an additional 2,400 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Haemonetics by 1.0% during the fourth quarter. Principal Financial Group Inc. now owns 156,734 shares of the medical instruments supplier’s stock worth $12,238,000 after acquiring an additional 1,475 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Up 1.4 %

Shares of NYSE:HAE opened at $65.50 on Monday. The business’s 50 day simple moving average is $70.86 and its 200 day simple moving average is $76.02. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market capitalization of $3.29 billion, a P/E ratio of 25.79, a P/E/G ratio of 1.11 and a beta of 0.39.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Needham & Company LLC dropped their price target on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. JMP Securities dropped their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price target for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.